Delivery of epidrugs

Fatima el Bahhaj; Frank J Dekker; Nadine Martinet; Philippe Bertrand

doi:10.1016/j.drudis.2014.03.017

Delivery of epidrugs

Fatima el Bahhaj, Frank J Dekker, Nadine Martinet, Philippe Bertrand

Research output: Contribution to journal › Review article › peer-review

19 Citations (Scopus)

Abstract

Inhibitors of epigenetic targets have entered clinical trials with some success, in particular for combined therapies. Like many other chemotherapeutics these new classes of molecules have dose-limiting toxicities and highly active metabolism in vivo resulting in lower efficacy than expected. This review presents drug delivery strategies proposed to prolong epigenetic inhibitor effects while reducing toxicities and metabolic clearance. Inspired from the work done in cancer-targeted strategies, prodrugs and nanoparticle-based drug delivery systems are discussed in a comprehensive way, detailing the chemical and physiological principles of the selected releasing method and, when available, how epigenetic chemistry can be exploited.

Original language	English
Pages (from-to)	1337-1352
Number of pages	16
Journal	Drug Discovery Today
Volume	19
Issue number	9
DOIs	https://doi.org/10.1016/j.drudis.2014.03.017
Publication status	Published - Sept-2014

Access to Document

10.1016/j.drudis.2014.03.017

Handle.net

Persistent link

Cite this

@article{2d34c0c96a5e4f5b8d5e6ba551dfbfa4,

title = "Delivery of epidrugs",

abstract = "Inhibitors of epigenetic targets have entered clinical trials with some success, in particular for combined therapies. Like many other chemotherapeutics these new classes of molecules have dose-limiting toxicities and highly active metabolism in vivo resulting in lower efficacy than expected. This review presents drug delivery strategies proposed to prolong epigenetic inhibitor effects while reducing toxicities and metabolic clearance. Inspired from the work done in cancer-targeted strategies, prodrugs and nanoparticle-based drug delivery systems are discussed in a comprehensive way, detailing the chemical and physiological principles of the selected releasing method and, when available, how epigenetic chemistry can be exploited.",

author = "{el Bahhaj}, Fatima and Dekker, {Frank J} and Nadine Martinet and Philippe Bertrand",

year = "2014",

month = sep,

doi = "10.1016/j.drudis.2014.03.017",

language = "English",

volume = "19",

pages = "1337--1352",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "ELSEVIER SCI LTD",

number = "9",

}

TY - JOUR

T1 - Delivery of epidrugs

AU - el Bahhaj, Fatima

AU - Dekker, Frank J

AU - Martinet, Nadine

AU - Bertrand, Philippe

PY - 2014/9

Y1 - 2014/9

N2 - Inhibitors of epigenetic targets have entered clinical trials with some success, in particular for combined therapies. Like many other chemotherapeutics these new classes of molecules have dose-limiting toxicities and highly active metabolism in vivo resulting in lower efficacy than expected. This review presents drug delivery strategies proposed to prolong epigenetic inhibitor effects while reducing toxicities and metabolic clearance. Inspired from the work done in cancer-targeted strategies, prodrugs and nanoparticle-based drug delivery systems are discussed in a comprehensive way, detailing the chemical and physiological principles of the selected releasing method and, when available, how epigenetic chemistry can be exploited.

AB - Inhibitors of epigenetic targets have entered clinical trials with some success, in particular for combined therapies. Like many other chemotherapeutics these new classes of molecules have dose-limiting toxicities and highly active metabolism in vivo resulting in lower efficacy than expected. This review presents drug delivery strategies proposed to prolong epigenetic inhibitor effects while reducing toxicities and metabolic clearance. Inspired from the work done in cancer-targeted strategies, prodrugs and nanoparticle-based drug delivery systems are discussed in a comprehensive way, detailing the chemical and physiological principles of the selected releasing method and, when available, how epigenetic chemistry can be exploited.

U2 - 10.1016/j.drudis.2014.03.017

DO - 10.1016/j.drudis.2014.03.017

M3 - Review article

C2 - 24680930

SN - 1359-6446

VL - 19

SP - 1337

EP - 1352

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 9

ER -

Delivery of epidrugs

Abstract

Access to Document

Handle.net

Fingerprint

Cite this